Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of Metastatic and Localized human Pancreatic Neuroendocrine Tumors

ABSTRACT: RNA-seq analysis of Metastatic and Localized human Pancreatic Neuroendocrine Tumors

PROVIDER: PRJNA738879 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14853949_1.fastq.gz	Fastqsanger.gz
	SRR14853949_2.fastq.gz	Fastqsanger.gz
	SRR14853950_1.fastq.gz	Fastqsanger.gz
	SRR14853950_2.fastq.gz	Fastqsanger.gz
	SRR14853951_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

RNA-seq analysis of Metastatic and Localized human Pancreatic Neuroendocrine Tumors

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of RNAs in human pancreatic neuroendocrine tumor (PNET) tissues. We analyzed the transcriptome maps of primary tumor sites from patients that presented metastasis or not (localized). This analysis revelaed that the immune cell and pathway-related molecular signatures were enriched in metastatic compared to localized tumors. Given the wide change of gene expression in metastatic PNETs, we analyzed the RNA-seq data using a L1000 drug-induced signature to identify pharmacologic agents that might preferentially target metastatic disease. In a separate study, we analyzed our RNA-seq data to understand the molecular basis of sexual dimorphisms in PNETs. We found that PNETs are associated with the emergence of unique sex-specific transcriptomic differences that are not observed in non-neoplastic pancreatic islet tissues.

2022-06-30 | GSE178398 | GEO

Combined deletion of MEN1, ATRX and PTEN triggers pancreatic neuroendocrine tumorigenesis in mice

Project description:Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of tumors that exhibit an unpredictable and broad spectrum of clinical presentations and biological aggressiveness. Surgical resection is still the only curative therapeutic option for localized PanNET but the majority of patients are diagnosed at an advanced and metastatic stage with limited therapeutic options. Key factors limiting the development of new therapeutics are the extensive heterogeneity of PanNETs and the lack of appropriate clinically relevant models. In that context, genomic sequencing of human PanNETs revealed recurrent mutations and structural alterations in several tumor suppressors. Here, we demonstrated that combined loss of MEN1, ATRX, and PTEN, tumor suppressors commonly mutated in human PanNETs, triggers pancreatic neuroendocrine tumorigenesis in mice. Histopathological evaluation and gene expression analyses of the developed tumors confirm the presence of PanNET hallmarks and significant overlap in gene expression patterns found in human disease. Thus, we postulate that the presented novel genetically defined neuroendocrine-specific tumor mouse is the first clinically relevant immunocompetent in vivo PanNET model.

2024-04-17 | GSE248606 | GEO

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

Project description:Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors.

| PRJNA736305 | ENA

LC-MS of Human Blood of Pancreatic neuroendocrine tumors

Project description:Pancreatic Neuroendocrine tumors are challenging to diagnose and often detected at advanced stages due to lack of specific and sensitive biomarkers. This study utilized proteomics as a valuable approach for cancer biomarker discovery, therefore, mass spectrometry-based proteomic profiling was conducted on plasma samples from 12 subjects (3 controls; 9 PanNET patients) to identify potential proteins capable of effectively distinguish PanNET from healthy controls. 13.2% of proteins were uniquely identified in PanNET, while 60% were commonly expressed in PanNET and controls. 17 proteins exhibiting significant differential expression between PanNET and controls were identified with downstream analysis.

2024-01-26 | PXD045045 | Pride

Single-cell RNA-sequencing of metastatic pancreatic neuroendocrine tumor

Project description:Single-cell RNA-sequencing of metastatic pancreatic neuroendocrine tumor

| PRJNA682637 | ENA

Transcriptome of human non-functional pancreatic neuroendocrine tumors (PanNETs)

Project description:Transcriptome of human non-functional pancreatic neuroendocrine tumors (PanNETs)

| PRJNA484008 | ENA

MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

Project description:MicroRNA expression profile of different grade pancreatic neuroendocrine tumors

| PRJNA1104139 | ENA

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

Project description:Pancreatic neuroendocrine tumors (PanNETs) account for 1-3% of all neoplasms of the pancreas. Epigenetic changes seem to be the main drivers of PanNET tumorigenesis. Indeed, the most frequent mutated genes in PanNETs are DAXX (Death domain associated protein 6), ATRX (Transcriptional Regulator ATRX) and MEN1 (menin 1), which are all involved in epigenetic regulation. The objective of the project is to study the epigenetic changes undergoing in PanNETs. Specifically, we aimed at investigating whether do exist biologically important epigenetic differences in PanNET, useful for a clinically relevant classification.

2022-11-30 | E-MTAB-11962 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2022-11-30 | E-MTAB-11965 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2020-11-30 | E-MTAB-7924 | biostudies-arrayexpress